Relief of adverse events induced by chemotherapy is an important issue for patients, especially those with a poor prognosis, such as with pancreatic cancer. There are no reports of the relationship between gastroesophageal reflux disease (GERD) and chemotherapy, so we investigated the incidence of chemotherapy-induced GERD in patients undergoing treatment with gemcitabine or S-1 for pancreatic cancer and the effect of sodium rabeprazole (RPZ), a proton-pump inhibitor. GERD was diagnosed in 40% of the patients according to the Frequency Scale for Symptoms of GERD score, and RBZ therapy significantly improved their symptoms.
Get full access to this article
View all access options for this article.
References
1.
NeoptolemosJP, StockenDD, FriessH, BassiC, DunnJA, HickeyH, BegerH, Fernandez-CruzL, DervenisC, LacaineF, FalconiM, PederzoliP, PapA, SpoonerD, KerrDJ, BüchlerMW. European Study Group for Pancreatic Cancer: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med, 2004; 350:1200–1210.
2.
WadlerS, BensonAB3rd, EngelkingC, CatalanoR, FieldM, KornblauSM, MitchellE, RubinJ, TrottaP, VokesE. Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol, 1998; 16:3169–3178.
3.
RubensteinEB, PetersonDE, SchubertM, KeefeD, McGuireD, EpsteinJ, EltingLS, FoxPC, CooksleyC, SonisST. Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology: Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer, 2004; 100:2026–2046.
4.
SmithTJ, KhatcheressianJ, LymanGH, OzerH, ArmitageJO, BalducciL, BennettCL, CantorSB, CrawfordJ, CrossSJ, DemetriG, DeschCE, PizzoPA, SchifferCA, SchwartzbergL, SomerfieldMR, SomloG, WadeJC, WadeJL, WinnRJ, WozniakAJ, WolffAC. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol, 2006; 24:3187–3205.
5.
LatreilleJ, PaterJ, JohnstonD, LabergeF, StewartD, RusthovenJ, HoskinsP, FindlayB, McMurtrieE, YelleL, WilliamsC, WaldeD, ErnstS, DhaliwalH, WarrD, ShepherdF, MeeD, NishimuraL, OsobaD, ZeeB. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy:. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 1998; 16:1174–1178.
6.
NaeimA, DySM, LorenzKA, SanatiH, WallingA, AschSM. Evidence-based recommendations for cancer nausea and vomiting. J Clin Oncol, 2008; 26:3903–3910.
7.
SloanS. Rabeprazole-based therapy in the management of symptomatic gastroesophageal reflux disease. Am J Gastroenterol, 2003; 983:S49–S55.
8.
KusanoM, ShimoyamaY, SugimotoS, KawamuraO, MaedaM, MinashiK, KuribayashiS, HiguchiT, ZaiH, InoK, HorikoshiT, SugiyamaT, TokiM, OhwadaT, MoriM. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol, 2004; 39:888–891.
BurrisHA3rd, MooreMJ, AndersonJ, GreenMR, RothenbergML, ModianoMR, CrippsMC, PortenoyRK, StornioloAM, TarassoffP, NelsonR, DorrFA, StephensCD, Von HoffDD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol, 1997; 15:2403–2413.
11.
FriedenbergFK, XanthopoulosM, FosterGD, RichterJE. The association between gastroesophageal reflux disease and obesity. Am J Gastroenterol, 2008; 103:2111–2122.
12.
SkinnerDB. Pathophysiology of gastroesophageal reflux. Ann Surg, 1985; 202:546–556.
13.
OrlandoRC. Overview of the mechanisms of gastroesophageal reflux. Am J Med, 2001; 111,Suppl 8A:174S–177S.
14.
DickmanR, GreenC, FassSS, QuanSF, DekelR, Risner-AdlerS, FassR. Relationships between sleep quality and pH monitoring findings in persons with gastroesophageal reflux disease. J Clin Sleep Med, 2007; 3:505–513.
